PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

rifampin Side Effects

The reactions most often reported to the FDA for rifampin (also sold as Rifadin), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

13,451
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of rifampin come from 13,451 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 13,451 reports to the FDA Adverse Event Reporting System (FAERS) for rifampin (Rifadin): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

13,451

Reports Mentioning Death

1,383

10.3% of reports — not proof the medicine caused the death

Hospitalizations

5,402

40.2% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DRUG INTERACTION
970
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS
727
NAUSEA
628
CONDITION AGGRAVATED
550
PYREXIA
541
VOMITING
444
DRUG RESISTANCE
437
ACUTE KIDNEY INJURY
396
DYSPNOEA
380
DIARRHOEA
378
RASH
378
PARADOXICAL DRUG REACTION
363
COUGH
350
FATIGUE
335
DRUG-INDUCED LIVER INJURY
325
TREATMENT FAILURE
308

Who Reports Side Effects

Gender Distribution

Female 6,022 (50%)
Male 6,092 (50%)
Unknown 32

Age Distribution

0-17 1,065 (10%)
18-44 2,935 (29%)
45-64 2,796 (27%)
65-74 1,886 (18%)
75+ 1,576 (15%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,383 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 185
MULTIPLE ORGAN DYSFUNCTION SYNDROME 76
RESPIRATORY FAILURE 69
ACUTE KIDNEY INJURY 63
SEPSIS 63
DRUG INTERACTION 60
CONDITION AGGRAVATED 57
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 57
DYSPNOEA 55
THROMBOCYTOPENIA 54
GENERAL PHYSICAL HEALTH DETERIORATION 53
NAUSEA 51
DRUG-INDUCED LIVER INJURY 50
PNEUMONIA 50
TREATMENT FAILURE 50
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 49
SEPTIC SHOCK 49
CARDIAC ARREST 46

Reactions in Hospitalization Reports

Top reactions in 5,402 reports where hospitalization was an outcome.

Reaction Reports
DRUG INTERACTION 482
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 404
PYREXIA 336
NAUSEA 282
ACUTE KIDNEY INJURY 266
VOMITING 239
CONDITION AGGRAVATED 228
DIARRHOEA 185
DYSPNOEA 178
RASH 178
PARADOXICAL DRUG REACTION 162
THROMBOCYTOPENIA 154
DRUG-INDUCED LIVER INJURY 143
PNEUMONIA 135
COUGH 131
EOSINOPHILIA 131
ASTHENIA 129
FATIGUE 121

Compare rifampin vs amikacin →

What the FAERS Data Reveals About rifampin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 13,451 voluntary reports linked to rifampin and its brand equivalents (Rifadin), spanning 2004 through 2025. Of those, 1,383 (10.3%) listed death as an outcome and 5,402 (40.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 50% were female and 50% male; age distribution skews toward 18-44, with 2,935 reports in that bracket. The single most reported reaction is drug interaction with 970 submissions, followed by drug reaction with eosinophilia and systemic symptoms and nausea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.